Genetic Mechanisms in Human Hypertension RAAS Inhibition Study
Overview
- Phase
- Not Applicable
- Intervention
- Lisinopril, Atenolol
- Conditions
- Hypertension
- Sponsor
- Brigham and Women's Hospital
- Locations
- 1
- Primary Endpoint
- One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
- Status
- Withdrawn
- Last Updated
- 5 years ago
Overview
Brief Summary
The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.
Investigators
Gordon H. Williams, MD
Chief, Cardiovascular Endocrinology Section
Brigham and Women's Hospital
Eligibility Criteria
Inclusion Criteria
- •Male and female hypertensive participants who were previously studied in SCOR program.
Exclusion Criteria
- •Taking other medications beside thyroid or estrogen supplements.
Arms & Interventions
Lisinopril, Atenolol
Intervention: Lisinopril, Atenolol
Outcomes
Primary Outcomes
One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
Time Frame: 16 weeks